• Strengthening of the Company's governance, including new Board appointments and CEO transition
• Strategic decisions to sharpen focus on core products, reorganise resources, and partner with established market leaders for instrument development
• Progress in key markets, including strong respiratory sales, growing EMEA revenue, and securing first US commercial contracts

The announcement covers the key highlights from the 2025 Annual General Meeting of Genetic Signatures Ltd. It discusses the strengthening of the Company's governance, including the appointment of two new experienced ASX directors and the transition of the Chair role. The announcement also covers strategic decisions made during the past financial year, such as sharpening the focus on core products, reorganising resources, and choosing to partner with established market leaders for instrument development rather than developing an in-house automated instrument. The announcement outlines the progress made in key markets, including strong respiratory sales across all quarters, a 40% increase in EMEA revenue fueled by surging demand for enteric products, and the securing of the first US commercial contracts, marking a pivotal milestone. The Chair acknowledges the decline in the Company's share price over the past year but expresses confidence that the strategic changes made are critical to the Company's long-term value creation.

Q1 FY26 sales of $5.4 million, representing a 20% increase over the previous quarter and a 15% uplift compared to the prior corresponding period. This is the highest quarterly revenue since the COVID years. The Company has a strong balance sheet with $28.2 million in cash and term deposits as of 30 September 2025.

The Company's strategic priorities for FY26 include the development of a new automated solution and state-of-the-art software, further enhancements and improvements to workflows for on-market products, engaging NHS leaders in the UK to prioritise infection control and outbreak prevention, and concentrating commercial efforts on four high-priority US states to maximise market penetration.